Aster Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Aster Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-260	Closed	-$9.85K	–	1171
2026 Q1	$9.85K	Buy	+260	New	+$80.4K	﹤0.01%	628
2025 Q2	–	Sell	-62	Closed	-$2.39K	–	1456
2025 Q1	$2.39K	Sell	62 -55	-47%	-$3.44K	﹤0.01%	1170
2024 Q4	$9K	Buy	117 +108	+1,200%	+$7.82K	﹤0.01%	783
2024 Q3	$518	Buy	+9	New	+$486	﹤0.01%	1045

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aster Capital Management's PRAX Position: Q2 2026 in Review

Aster Capital Management sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 260 shares — an estimated $9.85K sold.

Aster Capital Management first reported a position in PRAX in Q3 2024 and held it in 4 quarters. The position peaked at $9.85K in Q1 2026. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Aster Capital Management reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
Aster Capital Management sold 260 Praxis Precision Medicines shares in Q2 2026, an estimated $9.85K.
Aster Capital Management first reported a position in Praxis Precision Medicines in Q3 2024 and held it in 4 quarters.
Aster Capital Management's Praxis Precision Medicines position peaked at $9.85K in Q1 2026.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.